Key Takeaways:
Praxis Precision Medicines announced its epilepsy drug elsunersen reduced seizures by a placebo-adjusted 77 percent in a trial of children with a rare genetic disorder.
“We are thrilled to see the remarkable, consistent results from EMBRAVE Part A, showing 77% reduction in monthly seizures and disease modifying improvements,” Praxis Precision Medicines said in a statement.
The EMBRAVE Part A trial showed 71 percent of patients treated with elsunersen achieved a greater than 50 percent reduction in seizures. Furthermore, 100 percent of patients on the drug saw improvements in sleep, motor function, and attention, compared to none on placebo.
The positive data significantly de-risks a key asset in Praxis’s pipeline, with the company expected to engage with regulatory authorities. The results could pave the way for a new treatment for SCN2A developmental and epileptic encephalopathy (DEE), a condition with high unmet medical need.
The company reported no treatment-emergent or serious adverse events related to elsunersen, a critical finding that strengthens the drug's profile as it moves toward potential regulatory submission. The sustained benefit was observed for up to one year in an open-label extension of the study.
The highly positive clinical trial data for elsunersen is expected to significantly increase investor confidence in Praxis Precision Medicines (PRAX). This breakthrough could lead to future regulatory approval and commercialization, representing a major value catalyst for the company. The next step will be discussions with the FDA to determine the path forward for elsunersen.
This article is for informational purposes only and does not constitute investment advice.
